Neurocrine Biosciences NBIX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $814.5M+42.2% | $805.5M+28.3% | $794.9M+27.8% | $687.5M+16.5% | $572.6M+11.1% | ||
| $13.8M+50.0% | $17.6M+89.2% | $14M+75.0% | $11.3M+22.8% | $9.2M+22.7% | ||
| $800.7M+42.1% | $787.9M+27.4% | $780.9M+27.2% | $676.2M+16.4% | $563.4M+10.9% | ||
| 98.3%-0.1pp | 97.8%-0.7pp | 98.2%-0.5pp | 98.4%-0.1pp | 98.4%-0.2pp | ||
| $296.2M+12.5% | $258.2M+39.1% | $250M+28.2% | $244.3M+27.8% | $263.2M+65.1% | ||
| $318.5M+15.2% | $301.8M+4.9% | $291.6M+24.5% | $286.3M+18.3% | $276.5M+13.7% | ||
| $621.1M+13.1% | $594.6M+22.4% | $555.9M+26.8% | $541.9M+21.8% | $549M+32.0% | ||
| $193.4M+719% | $210.9M+48.5% | $239M+30.0% | $145.6M+0.1% | $23.6M-76.2% | ||
| 23.7%+19.6pp | 26.2%+3.6pp | 30.1%+0.5pp | 21.2%-3.5pp | 4.1%-15.1pp | ||
| $53.4M+700% | $28.5M— | $52.8M+712% | $13.9M+130% | -$8.9M+86.3% | ||
| $246.8M+1,579% | $239.4M+47.2% | $291.8M+53.3% | $159.5M+61.8% | $14.7M-57.4% | ||
| $48.9M+619% | $85.7M+44.0% | $82.3M+36.0% | $52M+54.8% | $6.8M+176% | ||
| $197.9M+2,405% | $153.7M+49.1% | $209.5M+61.4% | $107.5M+65.4% | $7.9M-81.8% | ||
| 24.3%+22.9pp | 19.1%+2.7pp | 26.4%+5.5pp | 15.6%+4.6pp | 1.4%-7.0pp | ||
| $1.91+2,287% | $1.48+48.0% | $2.04+64.5% | $1.06+68.3% | $0.08-81.0% | ||
| $200.7M+543% | $218.4M+46.5% | $246.7M+29.6% | $152.9M+0.1% | $31.2M-70.4% | ||
| 24.6%+19.2pp | 27.1%+3.4pp | 31%+0.4pp | 22.2%-3.6pp | 5.4%-15.0pp | ||
| $193.4M+719% | $210.9M+48.5% | $239M+30.0% | $145.6M+0.1% | $23.6M-76.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences (NBIX) generated $3.1B in revenue over the trailing twelve months, up 28.6% year over year.
- Is Neurocrine Biosciences profitable?
- Neurocrine Biosciences reported $668.6M in net income over the trailing twelve months, a 21.6% net margin.
- What are Neurocrine Biosciences's profit margins?
- Gross margin is 98.2% and operating margin is 25.4%, with a 21.6% net margin.
- What is Neurocrine Biosciences's earnings per share?
- Neurocrine Biosciences's diluted EPS over the trailing twelve months is $6.49.
- Where does Neurocrine Biosciences's income statement data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
